Skip to main content

Generics

  • Report: Russian pharmacies sees spike in meldonium sales

  • CDC: 'Weakest' flu season in three seasons peaked in mid-March
    ATLANTA - For the week ended March 19, the Centers for Disease Control and Prevention reported that influenza activity decreased slightly, but remained elevated in the United States. Even so, by all indications the week ended March 12 may have been the peak of the 2015/2016 influenza season. 
     
    That means while this season may have started later than is typical, and lasted longer than is typical, the U.s. hasn't experienced a season with as few overall visits for influenza-like illness since the 2011/2012 season. 

  • Special DSN report examines pharmacy’s ‘impact’

    Drug Store News in March published the fifth edition of RxImpact, a special supplement to DSN, produced in support of the National Association of Chain Drug Stores’ RxImpact Day on Capitol Hill. The special Rx-Impact report — inserted in headquarter copies of this issue of DSN and delivered to all current members of the U.S.

  • Alembic launches generic Lamictal
    BRIDGEWATER, N.J. — Alembic Pharmaceuticals announced Thursday that it had launched its generic of Lamictal (lamotrigine) chewable dispersible tablets. The drug is indicated as an anticonvulsant used in the treatment of epilepsy and bipolar disorder.
     
    Alembic will offer the drug in 5- and 25-mg dosage strengths. This is Alembic’s 13th U.S. launch since the company began its U.S. operations. 

  • Health Canada reschedules naloxone, makes it available without prescription
    OTTOWA — Pharmacies in Canada can now dispense naloxone to patients without a prescription. Health Canada announced earlier this week that it had revised the Federal Prescription Drug use and reclassified naloxone as a Schedule II drug. 
     

  • Apple launches latest patient-friendly tool to manage health

  • FDA issues draft guidance on generic abuse-deterrent opioids
    SILVER SPRING, Md. — The Food and Drug Administration on Thursday issued a draft guidance aimed at facilitating the development of generic opioids with abuse-deterrent formulations (ADF). The agency said the new draft guidance is part of its plan to rethink how it approaches medications with opioids to combat widespread abuse. 
     

  • Ajanta launches generic immediate-release Keppra
    BRIDGEWATER, N.J. — Ajanta Pharma on Thursday announced the U.S. launch of its generic Keppra (levetiracetam) immediate-release tablets. The drug is indicated to treat partial onset seizures in adults and children. 
     
    The drug will be available in 250-, 500-, 750- and 1000-mg dosage strength. 
     
X
This ad will auto-close in 10 seconds